The majority (>60%) of breast cancers are ER-positive [1], whereas about 20% are negative for ER, PR, and HER2 expression (that is triple-negative breast cancer, TNBC) and most of these cancers have unfavorable clinical prognosis [2]. This evidence concerns the gene ESR1 and breast carcinoma.